{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:11:25Z","timestamp":1781842285854,"version":"3.54.5"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Idiopathic short stature (ISS) is a term used to describe a selection of short children for whom no precise aetiology has been identified. Molecular investigations have made notable discoveries in children with ISS, thus removing them from this category. However, many, if not the majority of children referred with short stature, are designated ISS. Our interest in defects of GH action, i.e. GH resistance, has led to a study of children with mild GH resistance, who we believe can be mis-categorised as ISS leading to potential inappropriate management. Approval of ISS by the FDA for hGH therapy has resulted in many short children receiving this treatment. The results are extremely variable. It is therefore important to correctly assess and investigate all ISS subjects in order to identify those with mild but unequivocal GH resistance, as in cases of PAPP-A2 deficiency. The correct identification of GH resistance defects will direct therapy towards rhIGF-I rather than rhGH. This example illustrates the importance of recognition of GH resistance among the very large number patients referred with short stature who are labelled as \u2018ISS\u2019.<\/jats:p>","DOI":"10.3389\/fendo.2021.781044","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T05:24:53Z","timestamp":1639113893000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["GH Resistance Is a Component of Idiopathic Short Stature: Implications for rhGH Therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Martin O.","family":"Savage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L.","family":"Storr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EC-20-0585","article-title":"Growth Failure: \u2018Idiopathic\u2019 Only After a Detailed Diagnostic Evaluation","volume":"10","author":"Rapaport","year":"2021","journal-title":"End Conn"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0023","article-title":"Evidence for a Continuum of Genetic, Phenotypic and Biochemical Abnormalities in Children With Growth Hormone Insensitivity","volume":"32","author":"David","year":"2011","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1210\/er.2018-00146","article-title":"Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action","volume":"40","author":"Storr","year":"2019","journal-title":"EndocriRev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(67)80197-5","article-title":"The Serum Growth-Hormone Response to Hypoglycemia in Dwarfism","volume":"71","author":"Frasier","year":"1967","journal-title":"J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/281544a0","article-title":"Direct Expression in Escherichia Coli of a DNA Sequence Coding for Human Growth Hormone","volume":"281","author":"Goeddel","year":"1979","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198107163050302","article-title":"Children With Normal-Variant Short Stature: Treatment With Human Growth Hormone for Six Months","volume":"305","author":"Rudman","year":"1981","journal-title":"N Eng J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198310273091703","article-title":"Growth Hormone Treatment for Short Stature","volume":"309","author":"Van Vliet","year":"1983","journal-title":"N Eng J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198408303110925","article-title":"Report of the Conference on Uses and Possible Abuses of Biosynthetic Human Growth Hormone","volume":"311","author":"Underwood","year":"1984","journal-title":"N Eng J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000184851","article-title":"Towards a Consensus on the Definition of Idiopathic Short Stature","author":"Ranke","year":"1996","journal-title":"Horm Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ghir.2007.11.004","article-title":"Idiopathic Short Stature: Definition, Epidemiology, and Diagnostic Evaluation","volume":"18","author":"Wit","year":"2008","journal-title":"GH IGF Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2007.11.003","article-title":"Idiopathic Short Stature: Management and Growth Hormone Treatment","volume":"18","author":"Wit","year":"2008","journal-title":"GH IGF Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0509","article-title":"Consensus Statement on the Diagnosis and Treatment of Children With Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop","volume":"93","author":"Cohen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000069321","article-title":"The Calculation of Target Height Reconsidered","volume":"59","author":"Hermanussen","year":"2003","journal-title":"Horm Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00019","article-title":"Genetic Testing for the Child With Short Stature-Has the Time Come To Change Our Diagnostic Paradigm","volume":"104","author":"Dauber","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03775","article-title":"The Continuum of Growth Hormone-IGF-I Axis Defects Causing Short Stature: Diagnostic and Therapeutic Challenges","volume":"72","author":"Savage","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy271","article-title":"GIANT Consortium Meta-Analysis of Genome-Wide Association Studies for Height and Body Mass Index in \u223c700000 Individuals of European Ancestry","volume":"27","author":"Yengo","year":"2018","journal-title":"Hum Mol Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.165","article-title":"Short and Tall Stature: A New Paradigm Emerges","volume":"11","author":"Baron","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0099","article-title":"The Growth Hormone-Insulin-Like Growth Factor-I Axis in the Diagnosis and Treatment of Growth Disorders","volume":"7","author":"Blum","year":"2018","journal-title":"Endocr Conn"},{"key":"B19","article-title":"A Hormonally Controlled Serum Factor Which Stimulates Sulfate Incorporation by Cartilage In Vitro","volume":"49","author":"Salmon","year":"1957","journal-title":"J Lab Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0526","article-title":"The Somatomedin Hypothesis 2007: 50 Years Later","volume":"92","author":"Kaplan","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B21","article-title":"Clinical Relevance of Systemic and Local IGF-I: Lessons From Animal Models","author":"LeRoith","year":"2008","journal-title":"Pediatr Endocrinol Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2005,06.011","article-title":"Insulin-Like Growth Factor (IGF-I) Measurements in Growth Hormone (GH) Therapy of Idiopathic Short Stature (ISS)","volume":"15","author":"Park","year":"2005","journal-title":"GH IGF Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0204","article-title":"American Norditropin Study Group. Insulin Growth Factor-Based Dosing of Growth Hormone Therapy in Children: A Randomized, Controlled Study","volume":"92","author":"Cohen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.11.8019","article-title":"The IGF-I Generation Test Revisited: A Marker of GH Sensitivity","volume":"86","author":"Buckway","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000074038","article-title":"Reproducibility in Patterns of IGF Generation With Special Reference to Idiopathic Short Stature","volume":"60","author":"Selva","year":"2003","journal-title":"Horm Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4008\/jcrpe.v1i3.53","article-title":"Controversies in the Definition and Treatment of Idiopathic Short Stature (ISS)","volume":"1","author":"Pedicelli","year":"2009","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.9.7850","article-title":"Study of GH Sensitivity in Chilean Patients With Idiopathic Short Stature","volume":"86","author":"Sjoberg","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41467-018-04521-0","article-title":"Dominant-Negative STAT5B Mutations Cause Growth Hormone Insensitivity With Short Stature and Mild Immune Dysregulation","volume":"9","author":"Klammt","year":"2018","journal-title":"Nat Comm"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201506106","article-title":"Mutations in Pregnancy-Associated Plasma Protein A2 Cause Short Stature Due to Low IGF-I Availability","volume":"8","author":"Dauber","year":"2016","journal-title":"EMBO Mol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0999","article-title":"Clinical and Biochemical Characteristics and Bone Mineral Density of Homozygous, Compound Heterozygous and Heterozygous Carriers of Three NovelMutations","volume":"176","author":"I\u015f\u0131k","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02065","article-title":"Phenotypic Features and Response to GH Treatment of Patients With a Molecular Defect of the IGF-I Receptor","volume":"104","author":"Walenkamp","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/js.2016-1119","article-title":"Novel Dominant-Negative GH Receptor Mutations Expands the Spectrum of GHI and IGF-I Deficiency","volume":"1","author":"Vairamani","year":"2017","journal-title":"J Endocr Soc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1086\/323266","article-title":"Pseudoexon Activation as a Novel Mechanism for Disease Resulting in Atypical Growth-Hormone Insensitivity","volume":"69","author":"Metherell","year":"2001","journal-title":"Am J Hum Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0042","article-title":"Phenotypic Spectrum and Responses to Recombinant Human IGF-I (rhIGF-I) Therapy in Patients With Homozygous Intronic Pseudoexon Growth Hormone Receptor Mutations","volume":"178","author":"Chatterjee","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0026","article-title":"Growth Hormone Receptor (GHR) Gene Transcript Heterogeneity may Explain Phenotypic Variability in Patients With Homozygous GHR Pseudoexon (6\u03a8) Mutation","volume":"9","author":"Chatterjee","year":"2020","journal-title":"Endocr Conn"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1007\/3-540-28902-X_11","article-title":"The Importance of the National Cooperative Growth Study (NCGS)","volume-title":"Deciphering Growth","author":"Hintz","year":"2005"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902183400702","article-title":"Effect of Growth Hormone Treatment on Adult Height of Children With Idiopathic Short Stature","volume":"340","author":"Hintz","year":"1999","journal-title":"N\u00a0Eng J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031457","article-title":"National Institute of Child Health and Human Development-Eli Lilly & Co. Growth Hormone Collaborative Group","volume":"89","author":"Leschek","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1641","article-title":"Controversy in Clinical Endocrinology: Problems With Reclassification of Insulin-Like Growth Factor I Production and Action Disorders","volume":"91","author":"Cohen","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3649","article-title":"Variation in Methods of Predicting Adult Height for Children With Idiopathic Short Stature","volume":"126","author":"Swatz Topor","year":"2010","journal-title":"Pediatrics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrendo.2018.22","article-title":"Growth Hormone - Past, Present and Future","volume":"14","author":"Ranke","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000098707","article-title":"KIGS International Board. Age at Growth Hormone Therapy Start and First-Year Responsiveness to Growth Hormone Are Major Determinants of Height Outcome in Idiopathic Short Stature","volume":"68","author":"Ranke","year":"2007","journal-title":"Horm Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/1687-9856-2013-9","article-title":"Characteristics of Children With Best and Poorest First- and Second-Year Growth During rhGH Therapy: Data From 25years of the Genentech National Cooperative Growth Study (NCGS)","volume":"9","author":"Kaplowitz","year":"2013","journal-title":"Int J Pediatr Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00775","article-title":"Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet\u00ae IOS and ANSWER Program","volume":"104","author":"S\u00e4vendahl","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000505","article-title":"Growth Hormone Treatment for Growth Hormone Deficiency and Idiopathic Short Stature: New Guidelines Shaped by the Presence and Absence of Evidence","volume":"29","author":"Grimberg","year":"2017","journal-title":"Curr Opin Pediatr"},{"key":"B46","unstructured":"International Classification of Pediatric Endocrine Diagnoses2016"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c7157","article-title":"Impact of Growth Hormone Therapy on Adult Height of Children With Idiopathic Short Stature: Systematic Review","volume":"342","author":"Deodati","year":"2011","journal-title":"Br Med J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01411","article-title":"Pharmacokinetics of IGF-I in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density","volume":"102","author":"Cabrera-Salcedo","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2751","article-title":"Treatment With Recombinant Human Insulin-Like Growth Factor-1 Improves Growth in Patients With PAPP-A2 Deficiency","volume":"101","author":"Mu\u00f1oz-Calvo","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab437","article-title":"Genetic Characterization of Short Stature Patients Presenting With Phenotypic and Endocrine Overlap of Known Growth Hormone Insensitivity Syndromes","volume":"106","author":"Andrews","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.781044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T05:25:08Z","timestamp":1639113908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.781044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":50,"alternative-id":["10.3389\/fendo.2021.781044"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.781044","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"article-number":"781044"}}